|Bid||5.10 x 1300|
|Ask||5.46 x 1100|
|Day's Range||5.13 - 5.41|
|52 Week Range||4.28 - 17.01|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could potentially identify breast cancers with uPA overexpression and monitor uPA activity during treatment using PET imaging. uPA is an established biomarker in current breast cancer clinical practice guidelines, and its presence is used to select appropriate drug treatment. Monopar has a panel of proprietary antibodies and antibody fragments to uPA and its receptor uPAR (such as MNPR-101). The company's antibody fragment (ATN-291 F(ab')2) conjugated to a copper radiotracer enabled rapid PET visualization of tumors with uPA overexpression in a human breast cancer model in mice. Price Action: MNPR shares are up 12.3% at $6.47 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaBioNTech Stock Is Trading Higher On First Annual Profit; Raises 2021 Production Target For COVID-19 Shots To 2.5B DosesFDA Accepts AbbVie's Atogepant US Review Application For Migraine© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.